
|Videos|August 17, 2021
Dr. Susan Slovin on treatment selection in metastatic castration-sensitive prostate cancer
Author(s)Urology Times staff
Advertisement
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











